EU Holds Virus Talks As Study Shows Pfizer Jab 94% Effective

EU holds virus talks as study shows Pfizer jab 94% effective

EU leaders met Thursday under the spectre of Europe's sluggish vaccine drive as a new study showed Pfizer's Covid jab to be 94 percent effective, raising hopes for mass immunisation campaigns to help end the pandemic

Brussels, (APP - UrduPoint / Pakistan Point News - 25th Feb, 2021 ) :EU leaders met Thursday under the spectre of Europe's sluggish vaccine drive as a new study showed Pfizer's Covid jab to be 94 percent effective, raising hopes for mass immunisation campaigns to help end the pandemic.

The news came as the World Health Organization (WHO) urged governments to try to better understand the long-term consequences of coronavirus on some sufferers, calling the impact of prolonged symptoms a "significant" burden.

The virus was centre stage at the virtual EU meeting where leaders were due to discuss Europe's vaccine procurement woes, and also debate so-called "green passports".

Ahead of the video-conference, Austria's Chancellor Sebastian Kurz and Bulgarian Prime Minister Boyko Borissov called for passes to be issued to allow Europeans who have been vaccinated to travel and socialise.

"We want to get back to normal as quickly as possible, have our old lives back and maximum freedom," Kurz tweeted.

The bloc has been plagued by vaccine supply problems and has come under fire for its stuttering rollout.

Just four percent of the EU's 450 million people have received at least one jab, according to an AFP tally, but European Commission chief Ursula von der Leyen said her goal is to have 70 percent of adults in the bloc vaccinated by mid-September.

- Israel, US lead vaccine rollouts - The Covid-19 vaccines are boosting hopes that countries can finally start to emerge from the pandemic that has killed more than 2.4 million people and infected at least 112 million worldwide.

But rollouts have been patchy so far and most of the 217 million vaccine doses administered globally have gone to wealthier countries, with Israel and the United States leading the way.

Britain, which has also forged ahead with its vaccine drive, said Thursday it was lowering its alert level from the highest tier, citing a dip in cases.

The latest data about the Pfizer vaccine came from a large real-world study published in the New England Journal of Medicine Wednesday that involved 1.2 million people in Israel, where 52 percent of the population has received at least one dose.

The jab's efficacy against symptomatic Covid-19 was 94 percent seven or more days after the second dose -- very close to the 95 percent achieved during clinical trials.

"This is the first peer-reviewed large scale evidence for the effectiveness of a vaccine in real world conditions," Ben Reis, a researcher at Harvard Medical school and one of the paper's authors, told AFP.

And on Thursday, Pfizer and BioNTech said they were looking into adding a third dose to their vaccine regimen, six to 12 months after the booster jab.

The firms also said they were talking to regulators about testing a modified version of their vaccine to target the more contagious South African variant.

- Plastic surgery boom - As spirits were buoyed over the good vaccine news, the WHO urged governments to look into long-term Covid, which causes some people to show symptoms for months, including tiredness, brain fog, and cardiac and neurological disorders.

"It's a clear priority for WHO, and of the utmost importance. It should be for every health authority," said Hans Kluge, regional director for WHO Europe.

In France, hopes of a return to normal on the sports front were dashed after more than a dozen rugby players and staff tested positive, forcing Sunday's Six Nations match against Scotland to be scrapped.

And in Japan, organisers of the delayed Olympic torch relay said fans could line the route when it kicks off next month, but cheering is strictly banned and social distancing will be enforced.

Some sex workers in Bangladesh's largest brothel started getting their vaccines, a health official said Thursday.

Beauty, 40, who goes by one name, said she was initially hesitant about getting the shot.

"But the health officials reassured us. Now we understand it is important as we meet many people every day," she said.

Meanwhile in the US, business has been unexpectedly booming for plastic surgeons who have seen an uptick in cosmetic procedures -- seemingly a Zoom-era speciality.

"It's something new when you have to stare at your face for a couple of hours a day, and there's only so much you can do with good lighting and good angles," said real estate trainee Hudson Young after a series of nips and tucks.